JP2003533479A5 - - Google Patents

Download PDF

Info

Publication number
JP2003533479A5
JP2003533479A5 JP2001583765A JP2001583765A JP2003533479A5 JP 2003533479 A5 JP2003533479 A5 JP 2003533479A5 JP 2001583765 A JP2001583765 A JP 2001583765A JP 2001583765 A JP2001583765 A JP 2001583765A JP 2003533479 A5 JP2003533479 A5 JP 2003533479A5
Authority
JP
Japan
Prior art keywords
compound
disease
condition
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001583765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003533479A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/016150 external-priority patent/WO2001087297A1/en
Publication of JP2003533479A publication Critical patent/JP2003533479A/ja
Publication of JP2003533479A5 publication Critical patent/JP2003533479A5/ja
Pending legal-status Critical Current

Links

JP2001583765A 2000-05-17 2001-05-17 カンナビノイド薬剤 Pending JP2003533479A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20493500P 2000-05-17 2000-05-17
US60/204,935 2000-05-17
PCT/US2001/016150 WO2001087297A1 (en) 2000-05-17 2001-05-17 Cannabinoid drugs

Publications (2)

Publication Number Publication Date
JP2003533479A JP2003533479A (ja) 2003-11-11
JP2003533479A5 true JP2003533479A5 (enExample) 2008-07-10

Family

ID=22760084

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001583765A Pending JP2003533479A (ja) 2000-05-17 2001-05-17 カンナビノイド薬剤
JP2001583763A Pending JP2003533478A (ja) 2000-05-17 2001-05-17 （３ｒ，４ｒ）−δ８−テトラヒドロカンナビノール−１１−酸に基づく細胞増殖の低減方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2001583763A Pending JP2003533478A (ja) 2000-05-17 2001-05-17 （３ｒ，４ｒ）−δ８−テトラヒドロカンナビノール−１１−酸に基づく細胞増殖の低減方法

Country Status (13)

Country Link
US (2) US6448288B1 (enExample)
EP (2) EP1307186A4 (enExample)
JP (2) JP2003533479A (enExample)
CN (2) CN1273123C (enExample)
AT (1) ATE406156T1 (enExample)
AU (5) AU6468001A (enExample)
CA (2) CA2409005A1 (enExample)
DE (1) DE60135557D1 (enExample)
HU (2) HUP0700038A2 (enExample)
IL (3) IL152892A0 (enExample)
NZ (2) NZ523029A (enExample)
RU (2) RU2272620C2 (enExample)
WO (3) WO2001087297A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
EP1509250B1 (en) * 2002-06-06 2008-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
WO2004058251A1 (en) * 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2006065793A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
WO2006065792A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
EP2578561A1 (en) * 2005-09-29 2013-04-10 Albany Molecular Research, Inc. Processes for the production of cannabidiol derivatives and intermediates thereof
US20070093519A1 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
ES2398676T3 (es) 2007-12-07 2013-03-20 Abbott Gmbh & Co. Kg Derivados de oxindol sustituidos con amidometilo y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina
EP2231644B1 (de) 2007-12-07 2014-01-15 AbbVie Deutschland GmbH & Co KG 5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
NZ586651A (en) 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
CN111233814A (zh) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 一种萜酚类化合物zkyy-057及其制备方法和应用
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US4880030A (en) * 1988-07-25 1989-11-14 Terry Paul E Safety flow control fluid shutoff device
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5635530A (en) * 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
ES1045342Y (es) * 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.

Similar Documents

Publication Publication Date Title
RU2002133868A (ru) Каннабиноидные лекарственные средства
JPH0564930B2 (enExample)
JP2003509349A5 (enExample)
JP2003500450A5 (enExample)
JPWO1992021345A1 (ja) 抗腫瘍効果増強のための及び腫瘍治療のための組成物
Kane et al. Superior vena caval obstruction due to small-cell anaplastic lung carcinoma: response to chemotherapy
JP2003519228A5 (enExample)
JP2002535370A5 (enExample)
Gershanovich et al. Results of clinical study of antitumor action of hydrazine sulfate
KR20040030788A (ko) 요실금 치료를 위한 아릴(또는 헤테로아릴)아졸릴카르비놀 유도체
JP2002544227A5 (enExample)
JP2002510690A5 (enExample)
JP2007045781A (ja) Ｔｓ−１／カンプトテシン類による化学放射線療法
CA2464309A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
WO2001034198A2 (en) Oncolytic combinations for the treatment of cancer
US20230167120A1 (en) Aryl-fused isoselenazole compound containing tetrazine substituent, synthesis method therefor, and use thereof
WO1992004028A1 (en) Antineoplastic effect potentiator and antineoplastic agent
JP2002522462A5 (enExample)
JP2006501245A5 (enExample)
MORFIT Lymphangioma of the Tongue: Treatment and Appraisal of Long-Term Results
AU731260B2 (en) Therapeutic treatment for sexual dysfunctions
JP2003534318A5 (enExample)
JP2003534317A5 (enExample)
JP2008515947A5 (enExample)
CA2576926A1 (en) Use of midostaurin for treating gastrointestinal stromal tumors